Elacestrant: a new FDA-approved SERD for the treatment of breast cancer

Bhatia, N; Thareja, S

Thareja, S (通讯作者)，Cent Univ Punjab, Sch Pharmaceut Sci, Dept Pharmaceut Sci & Nat Prod, Bathinda 151401, Punjab, India.

MEDICAL ONCOLOGY, 2023; 40 (6):

Abstract

Elacestrant (RAD-1901), a selective estrogen receptor degrader, was approved by USFDA on January 27, 2023, for the treatment of breast cancer. It has ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索